title: Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma.
abstract: OBJECTIVE
  Cisplatin (CDDP) is widely used for chemotherapy of oral squamous cell carcinoma (OSCC). However, the mechanism of resistance to CDDP is unclear. Recently, caveolin-1 was identified as being associated with both metastasis and multidrug resistance. In the present study, we showed that caveolin-1 expression is significantly related to chemosensitivity in OSCC.
  
  
  METHODS
  We established a CDDP-resistant cell line, H-1R, from the parental OSCC cell line, H-1. Caveolin-1 expression was determined by reverse transcriptase-polymerase chain reaction (RT-PCR) in both cell lines. We analyzed expression of caveolin-1 in 30 OSCC biopsy specimens and investigated the relationship between expression of caveolin-1 and patients' clinicopathological parameters and chemotherapeutic responses.
  
  
  RESULTS
  The 3-(3,4-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay indicated that H-1R has a ten-times greater resistance to CDDP than H-1 has. The level of caveolin-1 expression in H-1R was significantly decreased in comparison with that in H-1 by real-time RT-PCR analysis. Positive caveolin-1 immunostaining correlated positively with a complete response (16/20, 80.0%). However, negative immunostaining was found in 6/7 (85.7%) cases with no response. Positive immunohistochemical staining of caveolin-1 correlated positively with chemosensitivity to CDDP-based combination chemotherapy (P=0.02).
  
  
  CONCLUSIONS
  These results suggest that overexpression of the caveolin-1 gene may provide novel diagnostic markers associated with CDDP sensitivity in OSCC.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. n-gen@wakayama-med.ac.jp
authors.forename: Ken
authors.initials: K
authors.lastname: Nakatani
authors.forename: Takeshi
authors.initials: T
authors.lastname: Wada
authors.forename: Megumi
authors.initials: M
authors.lastname: Nakamura
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Uzawa
authors.forename: Hideki
authors.initials: H
authors.lastname: Tanzawa
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Fujita
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D051242:Caveolin 1; D022461:Caveolins / Q000235:genetics*; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005887:Gingival Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D017663:Peplomycin / Q000008:administration & dosage; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D014162:Transfection; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; C495540:CAV1 protein, human; D051242:Caveolin 1; D022461:Caveolins; D012333:RNA, Messenger; D017663:Peplomycin; D014747:Vinblastine; D002945:Cisplatin